Floatz logo

pt-112

Metastatic Castrate-resistant Prostate Cancer

Promontory Therapeutics Inc.Phase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Metastatic Castrate-resistant Prostate Cancer cohort.

Asset / SponsorPhaseRating
IMIFOPLATIN
Promontory Therapeutics Inc.
Phase 2CCC
TRC 253
Tracon Pharmaceuticals Inc.
Phase 1/2CCC
Axitinib
University of Wisconsin, Madison
Phase 1CC

Same molecule, other indications

pt-112 is also rated in:

CRPCDormant
CCC
Indicative ·
53 / 100
View asset →
mCRPCDormant
CCC
Indicative ·
53 / 100
View asset →
PT-112Dormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →